Ferric Citrate Reduces Intravenous Iron and Erythropoiesis-Stimulating Agent Use in ESRD.

Autor: Umanath K; Division of Nephrology and Hypertension, Henry Ford Hospital, Detroit, Michigan; kumanat1@hfhs.org., Jalal DI; Renal Diseases and Hypertension, University of Colorado, Denver, Colorado;, Greco BA; Western New England Renal and Transplant Associates, Baystate Medical Center, Springfield, Massachusetts;, Umeukeje EM; Divisions of Nephrology and Hypertension and., Reisin E; Section of Nephrology and Hypertension, Louisiana State University Health Science Center, New Orleans, Louisiana;, Manley J; Mountain Kidney and Hypertension Associates, Asheville, North Carolina;, Zeig S; Pines Clinical Research, Pembroke Pines, Florida;, Negoi DG; Division of Nephrology, University of Vermont, Burlington, Vermont;, Hiremath AN; Nephrology and Hypertension Clinic, Southgate, Michigan;, Blumenthal SS; Division of Nephrology, Medical College of Wisconsin, Milwaukee, Wisconsin;, Sika M; Divisions of Nephrology and Hypertension and., Niecestro R; Independent Consultant, Pocono Pines, Pennsylvania; and., Koury MJ; Hematology and Oncology, Vanderbilt University Medical Center, Nashville, Tennessee;, Ma KN; Department of Population Health Sciences, University of Utah, Salt Lake City, Utah., Greene T; Department of Population Health Sciences, University of Utah, Salt Lake City, Utah., Lewis JB; Divisions of Nephrology and Hypertension and., Dwyer JP; Divisions of Nephrology and Hypertension and.

Publikováno v: Journal of the American Society of Nephrology : JASN [J Am Soc Nephrol] 2015 Oct; Vol. 26 (10), pp. 2578-87. Date of Electronic Publication: 2015 Mar 03.